amiodarone + sotalol + mexiletine

This entry refers to the antiarrhythmic drug (AAD) therapy arm used in a clinical trial (NCT04049019) conducted by IRCCS Ospedale San Raffaele for the treatment of ventricular tachycardia (VT). The therapy involves the administration of either amiodarone, sotalol, or mexiletine, depending on the patient's prior treatment history and the clinician's discretion. Amiodarone is a Class III antiarrhythmic that blocks potassium, sodium, and calcium channels and has alpha- and beta-adrenergic blocking properties. Sotalol is a non-selective beta-blocker with Class III antiarrhythmic properties (potassium channel blockade). Mexiletine is a Class Ib antiarrhythmic that blocks inward sodium channels. This pharmacological approach is being compared against repeat catheter ablation guided by non-invasive programmed stimulation (NIPS) to reduce VT recurrence in patients with structural heart disease.

Other names

Antiarrhythmic Drug TherapyAAD Therapy